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SUMMARY
Genetic and epigenetic defects in Wnt/b-catenin signaling play important roles in colorectal cancer progres-
sion. Here we identifyDACT3, a member of the DACT (Dpr/Frodo) gene family, as a negative regulator of Wnt/
b-catenin signaling that is transcriptionally repressed in colorectal cancer. Unlike other Wnt signaling inhib-
itors that are silenced by DNA methylation, DACT3 repression is associated with bivalent histone modifica-
tions. Remarkably, DACT3 expression can be robustly derepressed by a pharmacological combination that
simultaneously targets both histone methylation and deacetylation, leading to strong inhibition of Dishev-
elled (Dvl)-mediated Wnt/b-catenin signaling and massive apoptosis of colorectal cancer cells. Our study
identifies DACT3 as an important regulator of Wnt/b-catenin signaling in colorectal cancer and suggests a
potential strategy for therapeutic control of Wnt/b-catenin signaling in colorectal cancer.INTRODUCTION
Aberrant activation of Wnt/b-catenin signaling is a major driving
force in colon cancer (Kinzler and Vogelstein, 1996; Su et al.,
1992; van de Wetering et al., 2002). Mutations in Wnt/b-catenin
pathway components including APC, Axin, and b-catenin itself
are well-established causes of aberrant signaling activation
leading to cancer (Lammi et al., 2004; Liu et al., 2000; Morin
et al., 1997; Su et al., 1992). These genetic defects share in com-
mon that they result in the accumulation of b-catenin in the nu-
cleus. Nuclear b-catenin interacts with members of the TCF/
LEF transcription cofactor family to activate downstream target
genes such as Cyclin D1 and Myc that can lead to cell transfor-
mation (He et al., 1998; Morin et al., 1997; Tetsu and McCormick,1999; van de Wetering et al., 2002). The fact that blockade of
Wnt/b-catenin signaling in colon cancer cells induces apoptosis
or growth inhibition both in vitro and in vivo (Fujii et al., 2007; He
et al., 2005; Kwong et al., 2002) has propelled intensive efforts to
develop therapeutic strategies that target this pathway (Barker
and Clevers, 2006; Lepourcelet et al., 2004; Li et al., 2002).
In addition to genetic mutations in Wnt/b-catenin pathway
components, epigenetic events can also contribute to abnormal
activation of this signaling pathway in cancer cells. For example,
promoter methylation leading to transcriptional silencing of ex-
tracellular Wnt inhibitors, such as Secreted Frizzled-Related Pro-
teins (SFRPs), Wnt Inhibitory Factor-1 (WIF-1), and DICKKOPF-1
(DKK-1), have been reported in human colorectal cancer cells
(Aguilera et al., 2006; He et al., 2005; Morin et al., 1997; SuzukiSIGNIFICANCE
Wnt/b-catenin signaling is one of the most frequently deregulated pathways in colorectal cancer and is thus an important
therapeutic target. Our study identifies DACT3 as a negative regulator of Wnt/b-catenin signaling that is epigenetically re-
pressed in colorectal cancer. Repression of DACT3 in colon cancer does not require DNA methylation but instead involves
bivalent histone modifications. Of potential clinical importance, we identify a pharmacological approach that interferes with
this epigenetic process and robustly induces DACT3 expression, leading to inhibition of Wnt/b-catenin signaling and dra-
matic apoptosis of colon cancer cells. This work identifies an epigenetic component of Wnt/b-catenin regulation in colorec-
tal cancer and thereby opens an important avenue for pharmacological perturbation of this important cancer pathway.Cancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc. 529
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such as SFRP1/2 results in inhibition of Wnt/b-catenin signaling
and apoptosis of colorectal cancer cells even in the presence of
downstream APC or b-catenin mutations (Baylin and Ohm, 2006;
Suzuki et al., 2004). These findings suggest that epigenetic
silencing of upstream Wnt inhibitor genes contributes to trans-
formation through the amplification of aberrant signaling that
may be initiated by genetic mutations (Baylin and Ohm, 2006;
Suzuki et al., 2004). Consequently, epigenetic regulation of the
Wnt/b-catenin pathway has emerged as a potential therapeutic
target in human cancer, though previously published efforts in
this area have mainly focused on direct interference with TCF/
b-catenin-mediated transcriptional activation in cancer cells
(Barker and Clevers, 2006; Lepourcelet et al., 2004).
The identification of epigenetic regulators of Wnt/b-catenin
signaling may pave the way to developing innovative therapeutic
strategies. Members of the DACT (Dpr/Frodo) gene family have
been shown to modulate Wnt/b-catenin signaling by interacting
with Dishevelled (Dvl) (Cheyette et al., 2002), a central compo-
nent of Wnt signaling (Bilic et al., 2007; Logan and Nusse,
2004). DACT1 and DACT2 antagonize Wnt signaling in some
biological contexts, activate it in others, and may also play roles
in TGF-b/Nodal signaling (Gloy et al., 2002; Hikasa and Sokol,
2004; Su et al., 2007; Zhang et al., 2004, 2006). A third DACT
family member, DACT3, has been described in both mouse
and human (Fisher et al., 2006). However, the signaling function
of DACT3 and its relevance to oncogenesis are unclear.
RESULTS
DACT3 Expression Is Repressed in Colorectal Cancer
Independently of Promoter Methylation
To characterize epigenetic effectors of Wnt/b-catenin signaling in
colorectal cancer, we initially focused on 14 representative Wnt
signaling inhibitors, including members of the SFRP, WIF1,
DKK, and DACT gene families, some of which have previously
been shown to be transcriptionally inactivated or repressed in
various human cancers (Aguilera et al., 2006; He et al., 2005;
Suzuki et al., 2002, 2004). We determined gene expression in
24 human colorectal tumors versus matched normal mucosa,
using the Illumina Human Ref-8_V2 Sentrix BeadChip (Figure 1A
and Table S1 available online). We found that expression ofSFRP
family members was significantly reduced in nearly all human
colorectal tumor samples when compared to normal controls
(p < 0.001), a finding consistent with a previous report (Suzuki
et al., 2004). In contrast, expression of WIF-1 and DKKs in tumor
samples did not significantly differ from controls, despite previ-
ously reportedWIF-1 andDKK1 silencing in established colorec-
tal cancer cell lines (Aguilera et al., 2006; He et al., 2005). Interest-
ingly, expression of DACT3 was reduced in all 24 tumor samples
(p < 0.001), whereas expression levels of DACT1 and DACT2 did
not show significant differences between tumor and control
tissues (p = 0.24 and p = 0.64, respectively). Consistent with
reduced expression of Wnt inhibitors leading to enhanced base-
line Wnt/b-catenin signal activation, these tumors exhibited
increased expression of established b-catenin/TCF target genes,
including MYC (He et al., 1998), CCND1 (Tetsu and McCormick,
1999), LEF1 (Filali et al., 2002), and CD44 (Wielenga et al.,
1999), compared to control tissues. RT-PCR analysis of eight530 Cancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc.pairs of randomly selected patient samples confirmed repression
of SFRP1 and DACT3, but not of DACT1 in colorectal cancer
compared to controls (Figure 1B). Notably, we also found reduc-
tions in DACT2 expression in three out of eight tumor samples.
Thus, beyond previously identified reductions in expression of
Wnt inhibitors such as theSFRPs, we have found that the expres-
sion of DACT3 is also consistently reduced in colorectal cancer.
Additionally, we have found evidence that, in at least some
colorectal tumors, DACT2 expression is also reduced.
SFRPs have been shown to be transcriptionally inactivated in
cancer cells through promoter methylation (Suzuki et al., 2004).
To determine the methylation status of the DACT3 promoter,
we performed methylation-specific PCR (MSP) analysis in the
eight colorectal tumor samples around the transcription start
site as determined by 50RACE (Figure S1). The DACT3 promoter
contains a CpG island (Figure 1C). MSP analysis covering the en-
tire CpG island indicates a lack of DNA methylation at theDACT3
promoter in colorectal tumor samples (Figure 1C). As a positive
control, using the same technique we confirmed that the pro-
moter region of SFRP1 is methylated in these same tumor sam-
ples (Figure 1C). This finding suggests that, although DACT3
expression is reduced in colorectal cancer, this occurs indepen-
dently of the DNA methylation previously implicated in gene
silencing in these cells.
To determine whether the above observations are recapitu-
lated in colorectal cancer cell lines, we performed RT-PCR anal-
ysis of the DACT genes and of SFRP1 in seven such lines
(Figure 1D). UnlikeSFRP1, which is consistently silenced in colon
cancer, DACT3 shows a basal level of expression that varies in
different cell lines. Notably, expression of the other two DACT
family members, DACT1 and DACT2, was also lost in several of
these cell lines, though this was not true in the primary tumor tis-
sues examined above. We accordingly examined the methylation
status of all three DACT genes in these colorectal cancer cell
lines. As in the primary tumor samples, the DACT3 promoter is
unmethylated in all the cell lines tested, whereas DACT1 and
DACT2promoters were found to be partially and fully methylated,
respectively (Figure 1E). Bisulfite genomic sequencing (BGS) in
the RKO and HT29 cancer cell lines confirmed the results of
this MSP analysis, showing partially and nearly completely meth-
ylated CpGs in the DACT1 and DACT2 promoters, respectively,
but almost no methylated cytosines in the DACT3 promoter
(Figure 1F).
The DNMT inhibitor 5-aza-20deoxycytidine (5-AzaC) was used
to pharmacologically interfere with promoter methylation in the
HCT116 colorectal cancer cell line. 5-AzaC treatment decreased
methylation at the DACT1 and DACT2 promoters (Figure 1G),
leading to the increased expression of SFRP1, DACT1, and
DACT2, but not DACT3 (Figure 1H). Similarly, a HCT116 cell
line in which the DNA methyltransferase genes DNMT1 and
DNMT3B were genetically disrupted (Rhee et al., 2002) showed
decreased promoter methylation (Figure 1G; DKO) and in-
creased expression (Figure 1H) of DACT1, DACT2, and SFRP1
but no obvious change in DACT3 (Figures 1G and 1H). A similar
result was also obtained in DLD1 cells (Figure 1H). These results
support the conclusion that, unlike SFRP1 and the DACT1 and
DACT2 genes, promoter methylation does not contribute to the
epigenetic repression of DACT3 in colorectal cancer cells. Fur-
thermore, we found that in patient tumor samples the DACT1
Cancer Cell
DACT3 Inhibits b-Catenin Signaling in Colon CancerFigure 1. Loss of DACT3 Expression in Colon Cancer Independently of DNA Methylation
(A) Hierarchical clustering of Wnt inhibitors (upper) and Wnt/b-catenin target genes (lower) in human colorectal tumors (T) and matched normal mucosa (N).
(B) RT-PCR analysis of SFRP1 and DACT1, -2, and -3 from eight randomly selected pairs of human colorectal tumor and matched mucosa.
(C) Methylation status of SFRP1 and DACT3 in eight tumors determined by methylation-specific PCR (MSP) assay. M1, M2, M3, and M4 represent the examined
PCR regions covering the entire CpG island of DACT3 promoter.
(D) RT-PCR analysis of SFRP1 and DACT1, -2, and -3 in a panel of colorectal cancer cell lines compared to the normal tissue.
(E) Methylation status of SFRP1 and DACT1, -2, and -3 in colorectal cancer cell lines.
(F) Determination of methylation status of CpG sites by sequencing of bisulfite-modified DNA from normal and colorectal cancer cell lines. Arrows indicate the
transcription start sites. Open cycles represent unmethylated CpGs; closed cycles denote methylated CpGs.
(G) MSP analysis of DACT1, -2, and -3 promoters in HCT116 cells untreated or treated with 5-AzaC and in HCT116-DNMT1/DNMT3b/ (DKO) cells.
(H) RT-PCR analysis of SFRP1 and DACT1, -2, and -3 in HCT116 and DLD1 cells treated with 5-AzaC (5 mM) for 3 days and in DKO cells.promoter was not methylated, andDACT2 promoter methylation
is only detected in several tumor samples with reduced DACT2
expression (data not shown). Thus, the lack of methylation of
DACT1/2 in the clinical tumor samples we examined may explain
why they are not downregulated in these tumors in general.
Epigenetic Repression of DACT3 Is Associated with
Bivalent Histone Modifications
The above data suggest that epigenetic repression of DACT3 in
colon cancer might involve an alternative mechanism, such ashistone modification. To determine if chromatin status is associ-
ated with DACT3 repression, we used a chromatin immunopre-
cipitation (ChIP) assay coupled with quantitative PCR to charac-
terize potentially involved chromatin marks. To this end, we
designed a panel of eight to ten primer pairs covering a >7 kb re-
gion close to the transcription start site (TSS) of each of the three
DACT genes and searched for the presence of histone marks, in-
cluding the repressive marks H3K27me3, H3K9me3, H3K9me2,
and H4K20me3, as well as the activating marks H3K4me3 and
H3K9/14ac (Figure 2A). Abundant enrichment of the repressiveCancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc. 531
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ChIP assays were performed using antibodies against the indicated histone modifications and analyzed by quantitative PCR. Genomic DNA fragments covering
the 3.5 kb to +3.5 kb region with respect to the transcription start site of DACT1, -2, and -3 for PCR analysis were indicated with numbers. The relative enrich-
ments (bound/input) (mean ± SD of triplicate measurement) encompassing the indicated regions are shown for each histone mark at each gene locus.
(A) Histone marks at the DACT1–3 loci in HT-29 cells.
(B) Enrichments of H3K27me3 and H3K4me3 at the DACT3 locus in SW480 and RKO cells.
(C) Enrichments of H3K27me3 and H3K4me3 at the DACT3 locus in normal human intestinal epithelial cells (FHs 74 Int), noncancerous breast epithelial MCF10A
cells, and lung fibroblast MRC5 cells.H3K27me3, and to a lesser extent repressive H4K20me3, was
detected 500 bp downstream of the TSS ofDACT3 in HT29 cells.
In addition, a weaker H3K27me3 was also detected in the more
upstream promoter region of DACT3. This finding is in agree-
ment with several recent genome-wide studies showing that
the majority of H3K27me3 is detected in the proximal down-
stream region of the TSS in both cancer and embryonic stem
cells (Pan et al., 2007; Yu et al., 2007; Zhao et al., 2007). In con-
trast, no repressive H3K9 methylation marks were detected in
the DACT3 promoter region in HT29 cells.
The activating mark H3K4me3 was also detected at high levels
near the DACT3 TSS in HT29 cells, suggesting that the DACT3
promoter is simultaneously modified by both repressive and
activating (bivalent) histone methylation events in these cells.
Such bivalent histone states have previously been correlated
with genes transcribed at low levels (Azuara et al., 2006; Bern-
stein et al., 2006; Mikkelsen et al., 2007; Pan et al., 2007; Zhao
et al., 2007). If this is also true for theDACT3 locus, we would pre-
dict that the presence of repressive H3K27me3 should inversely
correlate with DACT3 expression levels. Consistent with this532 Cancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc.hypothesis, a high level of H3K27me3 was also detected at
DACT3 in SW480 cells that express low levels of DACT3;
H3K27me3 was detected to a lesser extent in RKO cells that
have modest DACT3 expression (Figure 2B). Moreover, only
a high level of only H3K4me3 (but not H3K27me3) was detected
at DACT3 in normal human intestinal epithelial cells (FHs 74 Int)
and two other noncancerous cell lines, breast epithelial MCF10A
and lung fibroblast MRC5 (Figure 2C), suggesting that this biva-
lent modification at DACT3 is cancer specific. To further confirm
that the DACT3 promoter is in a bivalent histone state in cells
where its expression is repressed, we have conducted whole-
genome mapping of major histone marks in SW480 cells using
ChIP-Seq Solexa technology. This high-resolution mapping of
histone modifications clearly demonstrates the comodification
of H3K27me3 and H3K4me3 at DACT3 (Figure S2).
Enrichments of H3K4me3, and to a lesser degree H3K27me3,
were also detected at DACT1, but no enrichment peaks of these
histone marks, including H3K4me3, were detected at theDACT2
locus (Figure 2A). In general for the DACT gene family, our results
suggest that the level of H3K4me3 is inversely correlated with the
Cancer Cell
DACT3 Inhibits b-Catenin Signaling in Colon CancerDNA methylation state: H3K4me3 is detected at the DACT1 pro-
moter (which is partially methylated), and at theDACT3 promoter
(which is not methylated), but not at the DACT2 promoter (which
is fully methylated) (compare Figures 1F and 2). This finding
agrees with recent reports that DNMT preferentially binds to un-
methylated H3K4 (Ooi et al., 2007) and that methylation of H3K4
tends to protect surrounding nucleotides from methylation
(Weber et al., 2007). Along with the earlier data showing that
expression of DACT3 is insensitive to CpG island methylation,
our data are consistent with the hypothesis that, in colon cancer
cells, DACT3 is repressed primarily through histone modifica-
tions, and specifically that the DACT3 locus in such cells exists
in a bivalent chromatin state simultaneously containing both
repressive and activating histone modifications.
Robust Derepression of DACT3 by a Pharmacological
Approach Inhibiting Both Histone Methylation
and Deacetylation
We have recently reported that the S-adenosylhomocysteine hy-
drolase inhibitor 3-Deazaneplanocin A (DZNep) depletes PRC2
components and inhibits histone methylation, including repres-
sive H3K27me3 and H4K20me3 (Tan et al., 2007). We set out
to test whether DZNep, alone or in combination with the histone
deacetylase inhibitor Trichostatin A (TSA), the DNMT inhibitor
5-AzaC, or both, could restore DACT3 expression in colorectal
cancer cells. To most accurately measure changes in gene
expression, we used the Illumina Beadarray, which allows for
accurate measurement of transcript levels without intermediate
nucleic acid amplification steps. We found that when used as
single agents these drugs minimally induce expression of
DACT3 in DLD1 cells (Figure 3A). However, combined treatment
with DZNep and TSA strongly induces DACT3 expression,
whereas other combinations such as DZNep/Aza or TSA/Aza
fail to do so (Figure 3A). By contrast, DZNep/TSA combination
only induced a modest increase in DACT1 expression (Fig-
ure 3B). Expression of DACT2, on the other hand, was only in-
duced by treatments containing 5-AzaC (Figures 1H and 3B),
consistent with its epigenetic silencing by more typical promoter
methylation.
To determine the specificity of DZNep/TSA combination treat-
ment for DACT3 derepression versus changes in expression of
other known Wnt/b-catenin pathway inhibitors, we again ana-
lyzed Illumina gene expression data using RNA from two colon
cancer cell lines (DLD1 and HT-29) that were untreated or treated
with DZNep, TSA, or both. This analysis revealed that DACT3 is
the only Wnt/b-catenin pathway inhibitor strongly induced by
DZNep/TSA treatment and that this occurred in both colon can-
cer cell lines (Figure 3B and Table S2). Together, our findings
show thatDACT3 is distinguished from other Wnt pathway inhib-
itors in that its repression in colon cancer cells seems to be
associated with the bivalent histone modifications but not DNA
methylation, and accordingly it can be robustly derepressed by
a pharmacologic approach that exclusively targets histone
modifications.
In order to better understand the mechanism whereby the
DZNep/TSA drug combination reactivates DACT3 expression,
we examined histone modification profiles in treated and un-
treated cells by western blot (Figure 3C). As previously reported,
DZNep treatment alone results in strong reduction of H3K27me3and H4K20me3, while having little effect on H3K9me3 (Tan et al.,
2007). Although the combination treatment resulted in some mild
inhibition of H3K9me3, the most notable synergistic change com-
pared to treatment with DZNep or TSA alone was robust induc-
tion of H3K9/14 acetylation (Figure 3C). Interestingly, H3K4me3
is also induced by this combination treatment, irrespective of
a slight decrease with DZNep treatment alone. Thus, the pharma-
cologic combination of DZNep with TSA causes an intriguing
global shift in histone modifications: it reduces certain repressive
histone marks (H3K27me3, H4K20me3, and H3K9me3) while
dramatically increasing some activating histone marks (H3K9/
14ac and H3K4me3). Mechanistically, this suggests the exis-
tence of crosstalk between these chromatin marks, such that
inhibition of repressive histone methylation by DZNep creates a
favorable chromatin environment for histone acetylation induced
by TSA. The magnitude of the effects observed on general
histone profiles in these treated cells further suggests that this
phenomenon is widespread throughout the genome. This in
turn leads to increased expression of specific target genes,
prominently including DACT3.
We used ChIP to further assess changes in histone modifica-
tions specifically at the DACT3 locus in response to DZNep/TSA
combination treatment. Consistent with the global changes in
modified histone levels found by western blot analysis, cells
treated with DZNep/TSA had a decrease in H3K27me3 and
H4K20me3, and a concomitant increase in H3K4me3 and
H3K9/14ac at the DACT3 locus (Figure 3D). Such effects were
much weaker at the DACT1 locus and thus correlate well with
the relative effects of this pharmacologic treatment on DACT3
and DACT1 gene expression, respectively. The striking changes
in histone methylation and acetylation marks at theDACT3 locus
are consistent with and help to explain the equally striking
changes inDACT3 expression levels following DZNep/TSA treat-
ment.
To summarize, our biochemical, pharmacologic, and expres-
sion data all support a model in which repression of DACT3 ex-
pression occurs via a bivalent histone domain. Furthermore, this
repression can be effectively reversed by a combined pharma-
cological approach that simultaneously inhibits both histone
methylation and deacetylation, resulting in a major change in
chromatic structure at a subset of such bivalently modified
genes, prominently including the DACT3 locus.
Derepression of DACT3 Is Associated with Inhibition
of Wnt/b-Catenin Signaling and Massive Apoptosis
in Colorectal Cancer Cells
Based on a previously published study (Zhang et al., 2006), one
effect of increased DACT protein levels might be degradation of
the Dishevelled (DVL) protein, which is central to Wnt signal
transduction (Bilic et al., 2007; Logan and Nusse, 2004). Activa-
tion of the Wnt/b-catenin pathway in cancer cells and in other
contexts is molecularly observable as accumulation of unphos-
phorylated non-membrane-associated b-catenin in the nucleus
and cytoplasm (Peifer and Polakis, 2000; Polakis, 2007). Accord-
ingly, we examined the effects of our drug treatment on DVL2
and b-catenin levels. DVL2 was arbitrarily chosen as a represen-
tative of the DVL gene family, as it is one of three functionally
redundant, conserved DVL family members expressed in all or
most cell types (Hamblet et al., 2002). Consistent with observedCancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc. 533
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(A) DACT3 mRNA expression analysis using Illumina Beadarray in DLD1 cells treated with 5 mM DZNep, 5 mM 5-AzaC, 200 nM TSA, or their combinations. The
data shown represent mean ± SD of three independent experiments.
(B) Indicated colorectal cancer cell lines were treated with DZNep, TSA, or both. RNA was harvested and subjected to array analysis. Changes of expression of
known Wnt/b-catenin antagonists are shown.
(C) Immunoblotting analysis of bulk histone modifications induced by DZNep, TSA, or both in HT29 cells and SW480 cells.
(D) ChIP analysis indicated the changes of histone marks at theDACT1 and DACT3 loci in HT29 cells untreated or treated with DZNep/TSA. The values represent
the normalized enrichments against the changes of a low background region before and after the drug treatment. The data represent mean ± SD of three
independent experiments.changes in transcript levels, DACT3 protein levels were markedly
increased (in both SW480 and DLD1 cells) upon DZNep and TSA
combination treatment as determined by western blot analysis
(Figure 4A and Figure S3). As predicted, the combination treat-
ment resulted in a decrease in DVL2 levels. In contrast, treatment
with either DZNep or TSA alone did not cause such changes
(Figure 4A). Concomitantly, levels of activated (nonphosphory-
lated) b-catenin dropped in DZNep/TSA-treated cells by western534 Cancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc.blot (Figure 4A). This was confirmed by immunocytochemistry
showing diminished nuclear b-catenin staining upon treatment
with DZNep/TSA (Figure 4B). Finally, the expression of TCF/b-
catenin target genes, including MYC, LEF1, CCND1, and CD44,
was markedly decreased in DZNep/TSA-treated cells, but not
in cells treated with either DZNep or TSA alone (Figure 4C and
Table S3). These findings uniformly indicate that Wnt/b-catenin
signaling is inhibited by DZNep/TSA combination treatment.
Cancer Cell
DACT3 Inhibits b-Catenin Signaling in Colon CancerFigure 4. Combination of DZNep and TSA Results in Blockade ofWnt/b-Catenin Signaling andMassive Apoptosis in Colorectal Cancer Cells
(A) Immunoblot analysis of DACT3, DVL2, total b-catenin, and nonphosphorylated b-catenin (Active-b-catenin) in SW480 and DLD1 cells treated with DZNep
(5 mM), TSA (100 nM), or both.
(B) Immunofluorescent images of DLD1 and SW480 cells treated with DZNep/TSA. b-catenin staining is red, and nuclear staining is green (DRAQ5). Scale bars
represent 10 mm.
(C) Indicated colorectal cancer cell lines were treated as above; RNA was harvested and subjected to array analysis. Changes of expression of known
Wnt/b-catenin target genes were shown using the gene clustering program. Green represents downregulated genes.
(D) DLD1 and HT29 cells were treated as in (A), and cell death was determined by PI staining and FACS analysis. The data represent mean ± SD of three
independent experiments.
(E) HT29 cells were treated as in (A), and Caspase-3 activity was measured by FACS analysis.
(F) HT29 cells were treated as in (A), followed by JC-1 staining and FACS analysis.Furthermore, we found that the decrease of b-catenin upon
DZNep/TSA can be effectively rescued by treatment of cells
with a small-molecule inhibitor of GSK-3, while the downregula-
tion of DVL2 remained unaffected (Figure S4). This suggests that
DACT3-DVL2 routes through GSK-3 to regulate b-catenin stabil-
ity. Among 81 genes whose expression was increased by
DZNep/TSA treatment in all the three cancer cell lines, DACT3
is by far the most heavily induced (Table S4). To our knowledge
no other gene in this list is directly relevant to Wnt/b-catenin
signaling. Taken together, our results support that DZNep/TSA
combination treatment decreases Wnt/b-catenin signal trans-
duction in colorectal cancer cell lines by increasing DACT3gene expression and protein levels, secondarily destabilizing en-
dogenous DVL proteins necessary for efficient Wnt signal trans-
duction. Conversely, they suggest that repression of DACT3 is
a key epigenetic event in colorectal cancer formation.
Inhibition of Wnt/b-catenin signaling is expected to block the
prosurvival pathway and induce apoptosis in cancer cells that
are addicted to this pathway (Fujii et al., 2007; He et al., 2005).
Indeed, we found that inhibition of Wnt/b-catenin signal trans-
duction by DZNep/TSA was accompanied by a strong synergis-
tic induction of cell death in DLD1 and HT29 cells, as assessed
by propidium iodide (PI) and fluorescence-activated cell sorting
(FACS) (Figure 4D). Similar results were obtained using otherCancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc. 535
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DACT3 Inhibits b-Catenin Signaling in Colon CancerFigure 5. DACT3Plays a Role in Inhibition of
Wnt/b-Catenin Signaling and Apoptosis
Induction by DZNep/TSA
(A) Two DLD1 stable clones expressing DACT3
shRNA (DACT3-sh1 and DACT3-sh2) or DLD1
cells expressing a nontargeting control shRNA
(NC) were treated with DZNep, TSA, or both.
DACT3 and actin mRNA levels were determined
by RT-PCR analysis; DVL2, active b-catenin, and
total b-actin protein levels were assessed by
immunoblotting.
(B) NC, DACT3-sh1, and DACT3-sh2 cells were
treated as above, and apoptosis was determined
by PI staining and FACS analysis. The data repre-
sent mean ± SD of three independent experi-
ments. **p < 0.01.
(C) SW480 cells transfected with DACT3 Smart-
Pool siRNA (DACT3-SP) and an independent
DACT3 siRNA (DACT3-2) were treated as in (A).
The data represent mean ± SD of three indepen-
dent experiments. **p < 0.05. DACT3 mRNA
levels, DVL2, active b-catenin protein levels, and
apoptosis were determined as previously.
(D) SW480 cells transfected with DACT1 siRNA
were untreated or treated with DZNep/TSA and
harvested for mRNA and apoptosis analysis as
above. The data represent mean ± SD of three
independent experiments.colon cancer cell lines (data not shown). In contrast, cells treated
with DZNep/Aza, a treatment that does not efficiently derepress
DACT3 expression, did not undergo comparable levels of cell
death. Similarly, addition of 5-AzaC to the DZNep/TSA combina-
tion, which does not produce further increases in DACT3 gene
expression, also does not produce additional increases in cell
death. This suggests that modulation of DNA methylation by
5-AzaC and resultant effects on other potential gene targets
does not contribute to further effects on Wnt/b-catenin signaling,
and that induction of DACT3 alone by DZNep/TSA is associated
with maximal cell death. The cell death induced by DZNep/TSA
was further determined to be apoptotic. As shown in Figure 4E,
DZNep/TSA combination treatment, but not single-agent treat-
ment, resulted in a dramatic activation of Caspase-3 in HT29
cells (Figure 4E). Moreover, the combination treatment induced
a sharp drop in mitochondrial transmembrane potential (MTP)
(DJm), indicative of mitochondrial dysfunction that is character-
istic of apoptosis (Figure 4F).
The specific effects of DZNep/TSA treatment on histone mod-
ifications, DACT3 gene expression, activated b-catenin protein
levels, and apoptosis were also seen in treatments combining
DZNep with other HDAC inhibitors such as PXD101 and sub-
eroylanilide hydroxamic acid (SAHA). This shows that the effects
of this pharmacological strategy that we have defined depend
on the combined action of DZNep with an HDAC inhibitor and
are not idiosyncratic consequences of TSA administered in
combination with DZNep (Figure S5).536 Cancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc.Functional Validation of DACT3 as a Critical
Regulator of Wnt/b-Catenin Signaling
To assess whether DACT3 transcriptional derepression is re-
quired to decrease Wnt/b-catenin signaling in treated colorectal
cancer cells, we generated cell lines derived from DLD1 that sta-
bly express a short-hairpin RNA targeting DACT3. Levels of the
DACT3 mRNA following DZNep/TSA treatment were greatly
diminished in two DLD1 clones expressing the DACT3 shRNA
compared to control shRNA cells (Figure 5A). Western blot anal-
ysis indicated that DZNep/TSA-induced effects on both DVL2
and unphosphorylated b-catenin levels were diminished in
DACT3 shRNA cells (Figure 5A). Moreover, when apoptosis
was assayed, the induction of apoptosis by DZNep/TSA was
markedly reduced in cell lines expressing DACT3 shRNA (Fig-
ure 5B). These DACT3 knockdown effects are unlikely to be
caused by off-target effects of the siRNA, because they were
also observed in SW480 cells transiently transfected with two
other independent DACT3 siRNAs (Figure 5C). By contrast,
knockdown of DACT1, which shows only a slight increase
upon DZNep/TSA treatment, had no inhibitory effect on apopto-
sis (Figure 5D). In summary, our results indicate that transcrip-
tional derepression of DACT3 contributes to inhibition of Wnt/
b-catenin signal transduction and to apoptosis following
DZNep/TSA treatment of colorectal cancer cells.
We next set out to directly test the function of DACT3 in regu-
lating Wnt/b-catenin signal transduction. DACT family members
in various species have previously been shown to interact with
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DACT3 Inhibits b-Catenin Signaling in Colon CancerFigure 6. Effects of DACT3 Overexpression on DVL2 and b-Catenin in Colorectal Cancer Cells
(A) Exogenously expressed DACT3 associates with DVL2. SW480 cells were transiently transfected with the indicated Flag- or HA-tagged expression constructs.
DACT3 was immunoprecipitated with anti-Flag, and the immunoprecipitates were probed with anti-HA antibody. Reciprocal coimmunoprecipitation between
DACT3 and DVL2 is shown on the lower panel.
(B) Western blot analysis of HA-tagged DVL2 protein levels in SW480 cells cotransfected with Flag-DACT3 or an empty vector.
(C) Immunofluorescent images of SW480 cells transfected with Myc-tagged DACT1 or DACT3 expression construct for 72 hr. Myc-tagged DACT1 or DACT3 and
b-catenin levels were detected by staining with anti-myc (red) and anti-b-catenin (green). Nuclei were stained by DRAQ5 (blue). Arrows indicate transfected cells
expressing DACT3-myc. Scale bar represents 10 mm.
(D) Colony formation assay showing ectopic expression of DACT3 suppresses colon cell growth. DLD1 cells were transfected with a DACT3 expression vector or
the empty vector and selected for 12 days with Zeocin. The number of colonies relative to the control in triplicates is shown on the right (error bar: mean ± SD).DVL proteins through a highly conserved C-terminal motif and to
negatively regulate b-catenin function (Cheyette et al., 2002;
Zhang et al., 2006). To confirm that DACT3 also interacts with
DVL proteins, we performed coimmunoprecipitation experi-
ments by transfecting SW480 cells with expression vectors for
Flag-tagged DACT3 and HA-tagged DVL2. Under these condi-
tions using either tag antibody, DVL2 efficiently immunoprecipi-
tates with DACT3, and conversely DACT3 efficiently immunopre-
cipitates with DVL2 (Figure 6A). Furthermore, cotransfection of
DVL2-HA with DACT3-Flag led to a marked decrease in DVL2-
HA protein expression compared to DVL2-HA-expressing cells
cotransfected with an empty vector (Figure 6B). These results
demonstrate that, as predicted from homology with other
DACT family members, DACT3 can indeed interact with DVL fam-
ily members as exemplified by DVL2. They further show that thisinteraction can reduce DVL protein stability, at least under these
cotransfection conditions.
We similarly investigated the effect of ectopic DACT3 expres-
sion on b-catenin levels in SW480 cells using confocal immuno-
chemistry. SW480 cells expressing Myc-tagged DACT3 or
DACT1 had nearly undetectable levels of nuclear b-catenin,
whereas untransfected cells or cells transfected with a nonrele-
vant gene product, Myc-tagged RPS27L, retained high levels of
nuclear b-catenin (Figure 6C). Moreover, SW480 cells ectopically
expressing DACT3 displayed condensed nuclei typical of apo-
ptosis. These results demonstrate that ectopically expressed
DACT3, like other Dact family members (Cheyette et al., 2002;
Hikasa and Sokol, 2004; Zhang et al., 2006), can negatively
regulate Wnt/b-catenin signaling, including in colorectal cancer
cells.Cancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc. 537
Cancer Cell
DACT3 Inhibits b-Catenin Signaling in Colon CancerTo determine if DACT3 suppresses cell growth as a result of
inhibition of oncogenic Wnt/b-catenin signaling, we performed
the colony formation assay with DLD1 cells transfected with
a DACT3-expressing plasmid or the control empty vector. Cells
transfected with DACT3 show a dramatic decrease in colony
numbers compared to control cells (Figure 6D). This result further
demonstrates that DACT3 functions as a potential tumor
suppressor in colon cancer.
DISCUSSION
The present study uncovers an epigenetic event that contributes
to the constitutive activation of Wnt/b-catenin signaling in human
colorectal cancer. We show that transcriptional repression of the
DACT3 gene occurs frequently both in colorectal cancer cell
lines and in patient-derived tumors. Our analysis indicates that
DACT3, together with SFRPs, might be a key epigenetic regula-
tor of the Wnt/b-catenin signaling pathway in this disease pro-
cess. This study thereby establishes DACT3 as a potentially
important target for cancer therapies aimed at controlling aber-
rant Wnt/b-catenin signaling.
Unlike the SFRP genes whose expression is often completely
silenced by promoter DNA methylation, DACT3 appears to be
expressed at low levels in colon cancer cell lines. We provide
evidence to show that this epigenetic event occurs through a
bivalent histone modification that contain both repressive
(H3K27me3) and activating (H3K4me3) histone marks at the
DACT3 locus and does not involve or require methylation of
the promoter DNA. As a result of this epigenetic regulation, levels
of DACT3 can be strongly induced by a pharmacological treat-
ment that targets histone modifications: specifically, combina-
tion treatment that simultaneously interferes with both histone
methylation and deacetylation. By contrast, this treatment
does not reactivate genes silenced predominately by DNA meth-
ylation, such as SFRP1 or DACT2, and only modestly induces
DACT1, whose repression in colon cancer cells is linked to
both DNA methylation and histone modifications. These data
suggest that this combination treatment of DZNep/TSA prefer-
entially reactivates genes predominately repressed by bivalent
histone modifications with minimum DNA methylation.
The bivalent chromatin state has been previously described in
both embryonic stem (ES) cells and some differentiated cells,
where it is in general associated with genes expressed at low
levels (Azuara et al., 2006; Barski et al., 2007; Bernstein et al.,
2006; Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al.,
2007). Some tumor suppressor genes with bivalent histone
marks in ES cells lose the H3K4me3 mark during oncogenesis,
but instead become fully silenced through DNA methylation
(Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter
et al., 2007). Our data suggest that a bivalent chromatin state oc-
curring in cancer cells might also contribute to cancerous trans-
formation. Importantly, this epigenetic modification atDACT3 lo-
cus appeared to be cancer specific, as we did not observe the
same modifications at the DACT3 locus in normal intestinal epi-
thelial cells. Genes found in such a bivalent chromatin state in
cancer cells (such as DACT3) therefore represent unique thera-
peutic targets. Unlike tumor suppressors that are silenced by
DNA methylation, genes carrying a bivalent chromatin such as
DACT3 may be more subject to manipulation by treatments538 Cancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc.such as DZNep/TSA that target both histone methylation and de-
acetylation. Identifying these alternatively regulated tumor sup-
pressor genes is also important because they are likely to be in-
sensitive to therapies that only target DNA methylation, such as
Aza.
Although highly speculative, it is possible that the chromatin
pattern we have observed at the DACT3 locus in our colorectal
cancer cells is part of the molecular signature of stem cell-like
cancer cells. There is evidence that Wnt/b-catenin signaling
plays a central role in the maintenance of epithelial stem cells
and of early progenitors (de Lau et al., 2007; Fodde and Brabletz,
2007). There is also data suggesting that the initial epigenetic
event(s) that upregulate Wnt/b-catenin signaling may occur in
colorectal adenomas before they acquire fully transforming
APC mutations (Siu et al., 1999; Suzuki et al., 2004). Bivalent his-
tone modification atDACT3 could be one such epigenetic event.
The combined pharmacologic approach we have described,
which targets an epigenetic signature characteristic of colorectal
cancer cells and abrogates Wnt/b-catenin signaling, may have
the potential to target cancer stem cells that rely on this mecha-
nism of gene silencing and that require high levels of Wnt/b-
catenin signaling activity for their self-renewal and survival.
Our study illustrates the diversity and complexity of epigenetic
mechanisms involved in gene repression in cancer cells. Use of
DZNep as a histone methylation inhibitor in combination with
other chromatin remodeling compounds may make it possible
to discover other cancer genes regulated through various epige-
netic mechanisms. The combined effects of DZNep and the
HDAC inhibitor TSA on overall histone modification profiles is
provocative, because together this drug combination appears
to switch a repressive chromatin state into an active one by
simultaneously reducing repressive histone marks (H3K27me3)
and increasing activating marks (H3K4me3 and H3K9/14ac).
This pharmacologic intervention, together with a DNA methyla-
tion inhibitor, might therefore have the potential to revert a glob-
ally ‘‘malignant’’ chromatin state found in some cancer cells into
a more normal ‘‘benign’’ one. Although it remains to be bio-
chemically determined how DZNep/TSA treatment generates
such strong synergy in histone acetylation, we propose that
this reflects direct crosstalk between these two types of histone
modification. We further predict that such pharmacologic epige-
netic ‘‘reprogramming’’ of histone modification profiles across
the genome can lead to profound changes in gene expression,
affecting multiple signaling pathways simultaneously. Indeed,
our microarray data shows that DACT3 is not the only gene reg-
ulated in this manner; the expression of at least 81 other genes
was significantly affected by combined DZNep/TSA treatment.
It is possible that inhibition of Wnt/b-catenin signaling cooper-
ates with other signaling effects to yield the maximal apoptotic
response observed upon this combination treatment.
We show that increasing the levels of DACT3 protein in colo-
rectal cancer cells, either through pharmacologic derepression
or via ectopic expression, results in robust degradation of DVL2
and to decreases in activated b-catenin. This DACT3-DVL2 sig-
naling interaction might route through GSK-3 to regulate b-cate-
nin stability; in support of this we have found that a small-mole-
cule inhibitor of GSK-3 can rescue the decreases in activated
b-catenin caused by DZNep/TSA treatment. As reported here
we have also found that decreases in activated b-catenin caused
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tations. This finding is consistent with numerous reports suggest-
ing that b-catenin phosphorylation and degradation still takes
place in colorectal cancer cells carrying APC mutations (Calviello
et al., 2007; Rice et al., 2003; Suzuki et al., 2004; Yang et al.,
2006). In particular, it has been shown that restored expression
of SFRP1/2 can effectively degrade b-catenin in colorectal can-
cer cells carrying these downstream mutations (Calviello et al.,
2007; Rice et al., 2003; Suzuki et al., 2004). These findings to-
gether with ongoing studies suggest that there are alternate mo-
lecular mechanisms that contribute to b-catenin regulation inde-
pendently of APC in colorectal cancer cells.
Our data also suggest that multiple abnormal epigenetic
events might contribute to aberrant activation of the Wnt/b-ca-
tenin signaling pathway in colon cancer. These multiple events
might occur in the same cell, or they may be present in different
cells within a tumor. By increasing heterogeneity in a tumor cell
population, epigenetic events may contribute to cancer progres-
sion and also contribute to treatment resistance and cancer
recurrence.
In short, this study demonstrates that epigenetic repression of
DACT3 leads to aberrant Wnt/b-catenin signaling in colorectal
cancer cells. Our data represent an important advance toward
understanding how this epigenetic event contributes to deregu-
lation of Wnt/b-catenin signaling in colorectal cancer. This work
also provides an important proof of principle that such epige-
netic events can be specifically targeted by pharmacologic strat-
egies to yield robust effects on Wnt/b-catenin signaling with
important consequences for cancer eradication.
EXPERIMENTAL PROCEDURES
Samples, Cell Lines, and Drug Treatment
Human tissue samples were obtained from the Singapore Tissue Network
using protocols approved by the Institutional Review Board of the National
University of Singapore; informed consent was obtained from each individual
who provided the tissues. The colorectal cancer cell lines and nontransformed
cell lines used in this study were purchased from the American Type Culture
Collection (Manassas, VA). HCT116 cells with genetic disruption of DNMT1
and DNMT3B (HCT116 DKO) were kindly provided by Dr. Bert Vogelstein
(Johns Hopkins University, MD). For drug treatment, cells were seeded the
day before the drug treatment. Cells were treated with 5 mM 3-Deazaneplano-
cin A (DZNep) (obtained from Dr. Victor E. Marquez at National Cancer Insti-
tute, USA) or 5 mM 5-AzaC (Sigma) for 72 hr and Trichostatin A (TSA; Cell
Signaling) at 100–200 nM for 24 hr. For 5-AzaC treatment, the medium was
replaced with freshly added 5-AzaC for every 24 hr. For cotreatment of cells
with DZNep and TSA, DZNep was added for 24 hr followed by TSA for an
additional 24 hr for gene expression analysis and 48 hr for FACS analysis.
Mapping of DACT3 Transcription Start Sites and Cloning
of Full-Length DACT3 cDNA
Total RNA (10 mg) was isolated from HEK293 cells with RNeasy Mini Kit (QIA-
GEN).DACT3 transcription start sites were mapped by RNA ligation-mediated
50RACE using FirstChoice RLM-RACE kit (Ambion) according to the manufac-
turer’s protocol with the exception of reverse transcription and PCR steps.
Reverse transcription after linker ligation was carried out at 64C for 1 hr using
Thermo-X polymerase (Invitrogen) and a gene-specific oligo: 50-GACCC
AGGCGACCATAGGAGCTGGATC-30. Nested PCR was carried out using
PfuUltraPhusion polymerase (Stratagene) with forward primers provided by
the FirstChoice RLM-RACE kit and gene-specific reverse primers: 50-GCTGG
ATCCAGAGAAGCCACTGTCCCCA-30 and 50-CACAGAAGGTTGAGGGTGG
TGAATCTGGACCT-30. PCR products were cloned into pCR-BluntII-TOPO
vector (Invitrogen) and sequenced with M13 primers. A taggedDACT3 expres-sion construct containing the longest open reading frame, based on mRNA
start site mapping, was generated for overexpression studies. Full-length
DACT3 coding region was amplified by RT-PCR using 5 mg of total mRNA
from HEK293 cells and the following primers: 50-ATTGAATTCAATGATCCGG
GCCTTCTCGTTCCCGGT-30 and 50-ATTAGATCTTCACACTGTAGTCATGAC
CTTGAGAGAACCCGA-30. The PCR product was cloned into p3xFLAG-
CMV10 between EcoRI and BglII sites and sequenced.
RNA Interference
The SMARTpool siRNA targeting DACT3 and the nontargeting control were
purchased from Dharmacon (Lafayett, CO). A separate DACT3 siRNA was
obtained from Sigma-Proligo that targeted the following sequence: 50-GGUUC
UCUCAAGGUCAUGA-30. To generate DACT3 shRNA stable cells, a DACT3
siRNA sequence (GGAGAAUCGCCUGCCUUCA) was cloned into the
pSIREN-RetroQ retroviral expression vector. The pSIREN-RetroQ-Neg Vector
was used as negative control shRNA (BD Bioscience), and cells were selected
and expanded as described (Tan et al., 2007).
Immunoblot Analysis
Immunoblotting was performed as described previously (Tan et al., 2007). The
blots were probed with the following antibodies. Anti-H3K27me3 (07-449),
anti-H3K9me3 (07-442), anti-H3K9/K14 ac (06-599), anti-H3K4me3 (07-473),
and anti-active b-catenin (05-665) were purchased from Upstate. Anti-
H4K20me3 (ab9053) was from Abcam. Anti-b-catenin (6B3) and anti-H3
(3H1) were from Cell Signaling, and anti-DVL2 (sc-8026) was from Santa
Cruz. The rabbit polyclonal antibody to DACT3 was raised against a 14 amino
acid peptide from human DACT3 (LSLESGGLEQESGR) and was purified
through affinity column.
Transfection and Immunoprecipitation
SW480 cells were transiently transfected using Fugene 6.0 (Roche). At 48 hr
posttransfection, the cells were lysed with 1 ml of lysis buffer (20 mM Tris-
HCl [pH 7.4], 2 mM EDTA, 25 mM NaF, 1% Triton X-100) plus protease inhib-
itors (Roche) for 30 min at 4C. After 12,000 3 g centrifugation for 30 min, the
lysates were immunoprecipitated with anti-FLAG M2 agarose affinity gel
(Sigma) or anti-HA affinity matrix (Roche) overnight at 4C. The precipitants
were washed three times with washing buffer (50 mM Tris-HCl [pH 8.0], 150
mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS),
and the immune complexes were eluted with sample buffer containing 1%
SDS for 5 min at 95C and analyzed by SDS-PAGE. Immunoblotting was per-
formed with primary antibodies against HA tag (sc-805, Santa Cruz) or FLAG
tag (F1804, Sigma).
Apoptosis and Flow Cytometric Analysis
Cells were harvested and fixed in 70% ethanol. Fixed cells were stained with PI
(50 mg/ml) after treatment with RNase (100 mg/ml). The stained cells were
analyzed for DNA content by FACS in a FACSCalibur (Becton Dickinson Instru-
ment, San Jose, CA). Apoptotic sub-G1 fraction was quantified using the
CellQuest software (Becton Dickinson). To measure the mitochondrial trans-
membrane potential (MTP), cells were stained with JC-1, according to the
manufacturer’s instructions (BD Bioscience), and cells positive for JC-1 detec-
tion were measured using CellQuest software (BD Bioscience). To measure
Caspase-3 activity, cells were fixed with Cytofix/Cytoperm solution (BD
Biosciences) as instructed and then stained with fluorescein isothiocyanate-
conjugated rabbit anti-active Caspase-3 monoclonal antibody (BD Biosci-
ences). Quantification of cells positive for the Caspase-3 detection was
performed by flow cytometry.
Microarray Gene Expression Analysis and Semiquantitative RT-PCR
Total RNA was isolated using Trizol (Invitrogen) and purified with the RNeasy
Mini Kit (QIAGEN). Reverse transcription was performed using an RNA Ampli-
fication kit (Ambion). The microarray hybridization was performed using the
Illumina Gene Expression Sentrix BeadChip HumanRef-8_V2, and data analy-
sis was performed using GeneSpring software from Agilent Technologies as
described (Tan et al., 2007). For RT-PCR, total RNA was reverse transcribed
using oligo(dT)12-18 primer with Superscript II reverse transcriptase (Invitro-
gen). cDNA (100 ng) was used for PCR, and the primer sequences are shownCancer Cell 13, 529–541, June 2008 ª2008 Elsevier Inc. 539
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database (accession number GSE10972).
DNA Methylation Analysis
The CpG island DNA methylation status was determined by PCR analysis after
bisulfited modification and followed by MSP and BGS (Yoshikawa et al., 2001).
All BGS and MSP primers were designed to be close transcription start sites
and in the CpG islands of the genes investigated. Primer sequences are shown
in Table S5.
ChIP Assays
ChIP assays were performed as described previously (Zhao et al., 2005).
The immunoprecipitated DNA was quantitated by real-time quantitative
PCR using the PRISM 7900 Sequence Detection System (Applied Biosys-
tems). Primer sets were chosen to amplify approximately 100–150 bp
around the indicated region. We used the following antibodies in the ChIP
study: anti-H3K27me3 (Upstate), anti-H3K9me3 and anti-H3K9me2
(Abcam), anti-H3K20me3 (Upstate), and anti-H3K9/14ac and anti-
H3K4me3 (Upstate). The enrichments of these histone marks at the examined
regions were quantitated relative to the input amount. To compare the two
pools of DNA materials, from cells untreated and from cells treated, a further
normalization of the DCt values against a region that shows low background
enrichment was performed. The sequences of the PCR primers are shown in
Table S5.
Immunofluorescence Staining and Confocal Microscopy
The cells were seeded in 4-well or 8-well culture chamber slides. After
treatment or transfection for 72 hr, cells were fixed with 3.7% paraformal-
dehyde in PBS and permeablized with 0.2% Triton X-100. Cells were
sequentially incubated with primary antibodies (anti-Myc or anti-b-catenin)
and Alexa Fluor 488- or Alexa Fluor 546-conjugated secondary antibodies
(Invitrogen) for 1 hr each and mounted in Fluorsave (Merck) mounting me-
dium. DRAQ5 (Biostats, UK) was diluted in mounting medium for nuclear
staining. The stained cells were examined by Zeiss LSM510 confocal
microscopy.
Colony Formation Assay
Colony formation assays were performed as described previously to evaluate
tumor cell growth in vitro (Yoshikawa et al., 2001). DLD1 cells were plated at
3 3 104 per well using 6-well plates and transfected with either pcDNA4.0-
DACT3 or backbone pcDNA4.0 (2.0 mg) using Fugene 6 (Roche) according
to the manufacturer’s protocol. The cells were replated in triplicates and cul-
tured for 10–15 days in complete DMEM medium containing Zeocin (100 mg/
ml). The surviving colonies were stained with Gentian violet after methanol
fixation, and visible colonies (350 cells) were counted.
ACCESSION NUMBERS
The microarray data have been submitted to the GEO public database at
http://www.ncbi.nlm.nih.gov/geo/ (accession number GSE10972).
SUPPLEMENTAL DATA
The Supplemental Data include five supplemental figures and five supplemen-
tal tables and can be found with this article online at http://www.cancercell.
org/cgi/content/full/13/6/529/DC1/.
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